Cargando…

Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro

Chidamide, a selective histone deacetylase inhibitor, has antitumour effects. 5-azacitidine (5-AZA), a hypomethylating agent, is effective in treating acute myeloid leukaemia (AML) and myelodysplastic syndrome. However, to the best of our knowledge, the effect of chidamide and 5-AZA on AML cell line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zheng, Zhang, Jian, Zhou, Min, Li, Jin-Li, Qiu, Qiao-Cheng, Fu, Jian-Hong, Xue, Sheng-Li, Qiu, Hui-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848469/ https://www.ncbi.nlm.nih.gov/pubmed/35103292 http://dx.doi.org/10.3892/or.2022.8277

Ejemplares similares

Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020)

P518: VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS
por: LI, Zheng, et al.
Publicado: (2023)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
por: Asai-Nishishita, Ai, et al.
Publicado: (2023)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2021)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
por: Jiang, Xuejie, et al.
Publicado: (2021)

Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia
por: Butrym, Aleksandra, et al.
Publicado: (2016)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Tan, P, et al.
Publicado: (2014)

Tetracenomycin X Exerts Antitumour Activity in Lung Cancer Cells through the Downregulation of Cyclin D1
por: Qiao, Xinran, et al.
Publicado: (2019)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
por: Seymour, John F., et al.
Publicado: (2017)

Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia
por: Samaiya, Misti, et al.
Publicado: (2011)

Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia
por: Young, Christine S., et al.
Publicado: (2015)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
por: Fenaux, P, et al.
Publicado: (2008)

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
por: Pleyer, Lisa, et al.
Publicado: (2016)

Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.
por: Kiue, A., et al.
Publicado: (1991)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
por: Lu, Yu, et al.
Publicado: (2022)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem, et al.
Publicado: (2023)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

COVID-19 in persons with chronic myeloid leukaemia
por: Li, Weiming, et al.
Publicado: (2020)

The role of BET epigenetic readers in acute myeloid leukaemia and other haematological malignancies
por: Huntly, Brian
Publicado: (2013)

Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives
por: Hou, Xi-Xi, et al.
Publicado: (2023)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1α pathway and generation of reactive oxygen species
por: Zhang, Hongyu, et al.
Publicado: (2017)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes
por: Gillberg, Linn, et al.
Publicado: (2019)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
por: Li, Jieqing
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n574b8ot2p2jhn8jc4j4ipi8gp